March 20, 2024
Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine
News
March 25, 2024
This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses
March 20, 2024
Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine
March 25, 2024
This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses